Resultados de la búsqueda 1-10 of 1198 for Adhesion

  1. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  2. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    These immune deficiency diseases are thought to be rare and include: Severe combined immunodeficiency (SCID), leukocyte adhesion deficiency (LAD), X-linked ...

  3. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  4. Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  5. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  6. Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  7. Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  8. Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  9. Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).

  10. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    The purpose of this study is to assess the long-term safety and effectiveness of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II).